^
Association details:
| Biomarker: | ALK rearrangement |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
Excerpt:
...- Patients must have an ALK rearrangement as defined via the MATCH Master Protocol...
Trial ID:
Source:
Title:
ALK‑positive locally advanced lung cancer in a patient who achieved long‑term complete response with crizotinib: A case report
Published date:
09/02/2022
Excerpt:
CONTRADICTING EVIDENCE: The present study reported a case of variant type 1 ALK‑rearranged stage 3B lung adenocarcinoma that maintained a complete response for >6 years under treatment with crizotinib. As first‑line treatment, crizotinib was administered twice daily (250 mg) and a complete response was confirmed after 3 months.
DOI:
https://doi.org/10.3892/etm.2022.11587
Source:
Title:
Successful therapy with bevacizumab combined with corticosteroids for crizotinib-induced interstitial lung disease
Excerpt:
We present the case of an old woman with ALK-rearranged stage IV lung adenocarcinoma who received crizotinib. She presented with severe dyspnea on the 34th day, and diffuse ground-glass opacifications in her chest. A diagnosis of crizotinib-induced ILD was confirmed. Corticosteroids were administered. However, the disease was still progressing rapidly.
DOI:
10.1007/s10456-019-09673-1
